Evidence map›Paper›PMID 40711337›Full record

ArticleVeterinary sciences2025

Chiari-like Malformation and Syringomyelia in Pomeranians: A Longitudinal Study.

Mees R Jansma, Marieke van den Heuvel, Kenny Bossens, Erik Noorman, Michelle Hermans, Paul J J Mandigers

Abstract read
In one paragraph

Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mees R JansmaDepartment of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, 3584 CM Utrecht, The Netherlands.
Marieke van den HeuvelDepartment of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, 3584 CM Utrecht, The Netherlands.ORCID 0009-0004-9208-026X
Kenny BossensNeurology Service, Orion Companion Animal Hospital, 2200 Herentals, Belgium.ORCID 0000-0003-0668-8996
Erik NoormanDierenkliniek Den Heuvel, 5684 NH Oirschot, The Netherlands.
Michelle HermansNeurology Service, Orion Companion Animal Hospital, 2200 Herentals, Belgium.ORCID 0000-0003-1640-2031
Paul J J MandigersDepartment of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, 3584 CM Utrecht, The Netherlands.ORCID 0000-0003-2547-6673

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChiari-like malformation (CM) and syringomyelia (SM) are commonly observed conditions in Pomeranian dogs. Affected dogs may develop clinical signs that significantly impact quality of life. Therefore, it is crucial to select only unaffected dogs for breeding. However, the progression of CM/SM has not been fully elucidated. Dogs that are unaffected or mildly affected may progress to severe SM over time. The primary aim of this study is to investigate the progression of CM/SM through repeated MRI scans. A secondary objective is to evaluate the effect of furosemide treatment on syrinx sizes, given its frequent prescription.

methodsPomeranians that underwent two CM/SM screenings between 2015 and 2025 were included. CM/SM classifications were assessed, and quantitative syrinx measurements were conducted. Maximum syrinx diameter (MSD) and maximum syrinx-to-spinal cord diameter ratio (MSD/SCD-r) were measured and documented. Dogs were classified based on the progression of SM. Furosemide treatment was documented, and its effect on syrinx size was compared with that in dogs not receiving furosemide.

resultsAt the time of the second MRI, 39.6% of dogs either developed SM or showed substantial progression, whereas 12.5% demonstrated partial recovery. Of the dogs initially classified as free from SM, 20.7% had developed the condition. A significant increase was observed in both MSD (

conclusionsThese findings indicate that syrinx dimensions are dynamic and may fluctuate over time, although a general trend toward progression is observed. Furthermore, furosemide may mitigate the progression of SM.

Indexed as

disease progressionfurosemidelate onset diseaseMRI

Identifiers

PMID40711337
PMCPMC12299236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.